Contrast-enhanced mammography (CEM), an imaging technique that uses iodinated contrast medium to allow the visualization of breast lesions and assess tumor neovascularity [1–8], was introduced commercially in 2011 [1,2]. Since then, its popularity has grown exponentially, as evidenced by the increasing numbers of CEM devices, examinations, and published studies [1].